SOLU-MEDROL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SOLU-MEDROL (SOLU-MEDROL).

How it works

Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses inflammatory cytokines and immune cell activity.

What the body does with it

Metabolism	Hepatic metabolism via CYP3A4
Excretion	Renal: approximately 80% as metabolites (glucuronide and sulfate conjugates) and unchanged drug; biliary/fecal: less than 5%.
Half-life	Terminal elimination half-life: 2.5–3.5 hours. In clinical context, the biologic half-life (suppression of HPA axis) is longer (24–36 hours) due to tissue retention of active metabolites.
Protein binding	Approximately 77% bound to corticosteroid-binding globulin (CBG) and albumin; binding is concentration-dependent.
Volume of Distribution	Vd: 0.8–1.0 L/kg. Indicates extensive tissue distribution, including penetration into cerebrospinal fluid.
Bioavailability	Intravenous: 100%; intramuscular: approximately 80–100% (highly variable due to injection conditions). Oral methylprednisolone (not Solu-Medrol itself) has bioavailability of 70–80%.
Onset of Action	Intravenous: within minutes (peak effect at 15–30 minutes); intramuscular: 1–2 hours; oral (not a typical route for Solu-Medrol, but methylprednisolone tablets): 1–2 hours.
Duration of Action	Duration of HPA axis suppression: 24–36 hours following a single dose. Clinical duration of anti-inflammatory effect may persist for 48–72 hours.

Classification & Brands

Action Class

Glucocorticoids

Brand Substitutes

Deposet 40mg Injection, Mepsonate 40mg Injection, Mypred 40mg Injection, Mepresso D 40mg Injection, Neo-Drol 40mg Injection, Celopred 500mg Injection, Mepresso 500mg Injection, Premisol 500mg Injection, Sol U Pred 500mg Injection, Methymic 500 Injection, Sanipred 125mg Injection, Predzen 125mg Injection, Elopred 125mg Injection, Succimed 125mg Injection, Premisol 125mg Injection, Lepred 250mg Injection, Desone 250mg Injection, Solu Medrol 250mg Injection

Dosing & administration

IV or IM: 10-40 mg methylprednisolone (as sodium succinate) every 4-6 hours; high-dose pulse therapy: 30 mg/kg IV over 30-60 minutes every 4-6 hours for 48-72 hours.

Dosage form	INJECTABLE
Renal impairment	No specific dose adjustment required for renal impairment; hemodialysis does not significantly remove methylprednisolone.
Liver impairment	Severe hepatic impairment (Child-Pugh class C): reduce dose by 50% or consider alternative; monitor for enhanced effects.
Pediatric use	IV/IM: 0.5-1.7 mg/kg/day in divided doses every 6-12 hours; pulse therapy: 30 mg/kg IV every 4-6 hours for 48-72 hours.
Geriatric use	Use lowest effective dose; monitor for hyperglycemia, osteoporosis, and fluid retention; consider reduced initial dose due to increased sensitivity.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SOLU-MEDROL (SOLU-MEDROL).

Breastfeeding	Methylprednisolone is excreted into breast milk in low amounts (M/P ratio approximately 0.5-1.0). Infant daily dose < 1% of maternal weight-adjusted dose. No known adverse effects in nursing infants with short-term use. Caution with high-dose or prolonged therapy due to potential adrenal suppression.
Teratogenic Risk	Pregnancy Category C. First trimester: Increased risk of oral clefts (odds ratio 1.3-3.4) based on epidemiological studies. Second/third trimester: Fetal adrenal suppression, growth restriction, and premature rupture of membranes with chronic high-dose use. No adequate controlled studies; use only if benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None (no FDA boxed warning).

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to methylprednisolone or any component","Systemic fungal infections","Live or live-attenuated vaccine administration","Intrathecal administration"]

Clinical Precautions

Precautions

["Immunosuppression and increased risk of infections","Adrenal suppression with prolonged use","Cushing's syndrome with prolonged use","Osteoporosis","Gastrointestinal perforation","Psychiatric disturbances","Ocular effects (cataracts, glaucoma)","Growth suppression in children","Fluid and electrolyte disturbances"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

SOLU-MEDROL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SOLU-MEDROL (SOLU-MEDROL).

How it works

Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses inflammatory cytokines and immune cell activity.

What the body does with it

Metabolism	Hepatic metabolism via CYP3A4
Excretion	Renal: approximately 80% as metabolites (glucuronide and sulfate conjugates) and unchanged drug; biliary/fecal: less than 5%.
Half-life	Terminal elimination half-life: 2.5–3.5 hours. In clinical context, the biologic half-life (suppression of HPA axis) is longer (24–36 hours) due to tissue retention of active metabolites.
Protein binding	Approximately 77% bound to corticosteroid-binding globulin (CBG) and albumin; binding is concentration-dependent.
Volume of Distribution	Vd: 0.8–1.0 L/kg. Indicates extensive tissue distribution, including penetration into cerebrospinal fluid.
Bioavailability	Intravenous: 100%; intramuscular: approximately 80–100% (highly variable due to injection conditions). Oral methylprednisolone (not Solu-Medrol itself) has bioavailability of 70–80%.
Onset of Action	Intravenous: within minutes (peak effect at 15–30 minutes); intramuscular: 1–2 hours; oral (not a typical route for Solu-Medrol, but methylprednisolone tablets): 1–2 hours.
Duration of Action	Duration of HPA axis suppression: 24–36 hours following a single dose. Clinical duration of anti-inflammatory effect may persist for 48–72 hours.

Classification & Brands

Action Class

Glucocorticoids

Brand Substitutes

Dosing & administration

IV or IM: 10-40 mg methylprednisolone (as sodium succinate) every 4-6 hours; high-dose pulse therapy: 30 mg/kg IV over 30-60 minutes every 4-6 hours for 48-72 hours.

Dosage form	INJECTABLE
Renal impairment	No specific dose adjustment required for renal impairment; hemodialysis does not significantly remove methylprednisolone.
Liver impairment	Severe hepatic impairment (Child-Pugh class C): reduce dose by 50% or consider alternative; monitor for enhanced effects.
Pediatric use	IV/IM: 0.5-1.7 mg/kg/day in divided doses every 6-12 hours; pulse therapy: 30 mg/kg IV every 4-6 hours for 48-72 hours.
Geriatric use	Use lowest effective dose; monitor for hyperglycemia, osteoporosis, and fluid retention; consider reduced initial dose due to increased sensitivity.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SOLU-MEDROL (SOLU-MEDROL).

Breastfeeding	Methylprednisolone is excreted into breast milk in low amounts (M/P ratio approximately 0.5-1.0). Infant daily dose < 1% of maternal weight-adjusted dose. No known adverse effects in nursing infants with short-term use. Caution with high-dose or prolonged therapy due to potential adrenal suppression.
Teratogenic Risk	Pregnancy Category C. First trimester: Increased risk of oral clefts (odds ratio 1.3-3.4) based on epidemiological studies. Second/third trimester: Fetal adrenal suppression, growth restriction, and premature rupture of membranes with chronic high-dose use. No adequate controlled studies; use only if benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None (no FDA boxed warning).

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to methylprednisolone or any component","Systemic fungal infections","Live or live-attenuated vaccine administration","Intrathecal administration"]